Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy
…, BK Nallamothu, SA Murphy, DJ Cohen, RJ Laham… - Circulation, 2006 - Am Heart Assoc
Background— It has been suggested that the survival benefit associated with primary
percutaneous coronary intervention (PPCI) in ST-segment elevation myocardial infarction may be …
percutaneous coronary intervention (PPCI) in ST-segment elevation myocardial infarction may be …
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial
M Simons, BH Annex, RJ Laham, N Kleiman, T Henry… - Circulation, 2002 - Am Heart Assoc
Background— Single-bolus intracoronary administration of fibroblast growth factor-2 (FGF2)
improved symptoms and myocardial function in a phase I, open-label trial in patients with …
improved symptoms and myocardial function in a phase I, open-label trial in patients with …
Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary
…, DJ Cohen, FJ Giordano, HK Hammond, RJ Laham… - Circulation, 2000 - Am Heart Assoc
The rapid development of angiogenic growth factor therapy for patients with advanced
ischemic heart disease over the last 5 years offers hope of a new treatment strategy based on …
ischemic heart disease over the last 5 years offers hope of a new treatment strategy based on …
Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo …
RJ Laham, FW Sellke, ER Edelman, JD Pearlman… - Circulation, 1999 - Am Heart Assoc
Background—Angiogenesis is a promising treatment strategy for patients who are not candidates
for standard revascularization, because it promotes the growth of new blood vessels in …
for standard revascularization, because it promotes the growth of new blood vessels in …
VEGF administration in chronic myocardial ischemia in pigs
JJ Lopez, R J. Laham, A Stamler… - Cardiovascular …, 1998 - academic.oup.com
Objective: Previous investigations have shown the effectiveness of sustained intra- or
extravascular administration of vascular endothelial growth factor (VEGF) in chronic myocardial …
extravascular administration of vascular endothelial growth factor (VEGF) in chronic myocardial …
Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study
RJ Laham, NA Chronos, M Pike, ME Leimbach… - Journal of the American …, 2000 - jacc.org
… Roger J Laham … Simons M, Laham R. Therapeutic angiogenesis in myocardial ischemia.
In: Ware, … Slavin J : "Fibroblast growth factors: at the heart of angiogenesis". Cell Biol Int 1995; …
In: Ware, … Slavin J : "Fibroblast growth factors: at the heart of angiogenesis". Cell Biol Int 1995; …
Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results
FW Sellke, RJ Laham, ER Edelman… - The Annals of thoracic …, 1998 - Elsevier
Background. Patients not amenable to complete myocardial revascularization by conventional
methods present a difficult clinical problem. Here we present the early results and …
methods present a difficult clinical problem. Here we present the early results and …
Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia
RJ Laham, M Rezaee, M Post, D Novicki… - … of Pharmacology and …, 2000 - ASPET
Therapeutic angiogenesis is a novel approach to the treatment of myocardial ischemia based
on the use of proangiogenic growth factors to induce the growth of new blood vessels to …
on the use of proangiogenic growth factors to induce the growth of new blood vessels to …
Preventing coronary obstruction during transcatheter aortic valve replacement: results from the multicenter international BASILICA registry
…, I George, P Mahoney, J Lanz, RJ Laham… - Cardiovascular …, 2021 - jacc.org
Objectives This study sought to determine the safety of the BASILICA (bioprosthetic or
native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction) …
native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction) …
[HTML][HTML] Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein
Objective: The long-term effects of surgical fibroblast growth factor 2 therapy are examined.
Methods: In a randomized, double-blind study, fibroblast growth factor 2 (10 μg or 100 μg) or …
Methods: In a randomized, double-blind study, fibroblast growth factor 2 (10 μg or 100 μg) or …